To examine the chemoresistance of CD44+ cells to anti-cancer chemotherapeutic agents, we performed cell survival assays for the CD44+ and CD44− cell fractions treated with fluorouracil (5-FU), cisplatin or doxorubicin. This evidence concerns the gene CD44 and cancer.